0000950170-24-002719.txt : 20240108 0000950170-24-002719.hdr.sgml : 20240108 20240108081617 ACCESSION NUMBER: 0000950170-24-002719 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20240108 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240108 DATE AS OF CHANGE: 20240108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TREACE MEDICAL CONCEPTS, INC. CENTRAL INDEX KEY: 0001630627 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 471052611 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40355 FILM NUMBER: 24518461 BUSINESS ADDRESS: STREET 1: 100 PALMETTO PARK PLACE CITY: PONTE VEDRA STATE: FL ZIP: 32081 BUSINESS PHONE: (904) 373-5940 MAIL ADDRESS: STREET 1: 100 PALMETTO PARK PLACE CITY: PONTE VEDRA STATE: FL ZIP: 32081 8-K 1 tmci-20240108.htm 8-K 8-K
false000163062700016306272024-01-082024-01-08

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 8, 2024

TREACE MEDICAL CONCEPTS, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

 

 

Delaware

001-40355

47-1052611

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification Number)

 

100 Palmetto Park Place

Ponte Vedra, Florida 32081

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (904) 373-5940

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

 

 

 

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value per share

TMCI

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 


 

Item 2.02. Results of Operations and Financial Condition.

 

On January 8, 2024, Treace Medical Concepts, Inc. issued a press release regarding certain preliminary unaudited financial results for the quarter and year-end December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

 

This information furnished under Item 2.02 of Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01

Financial Statements and Exhibits.

 

Exhibit No.

Description

99.1

Press Release of Treace Medical Concepts, Inc. issued on January 8, 2024

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

 

 

 

TREACE MEDICAL CONCEPTS, INC.

 

 

 

 

Date: January 8, 2024

 

By:

/s/ Mark L. Hair

 

 

 

Mark L. Hair

 

 

 

Chief Financial Officer

 

 


EX-99.1 2 tmci-ex99_1.htm EX-99.1 EX-99.1

 

Exhibit 99.1

img32504678_0.jpg 


Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2023 Revenue

Company to Present at J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 3:45 pm Pacific Time

PONTE VEDRA, Fla. – January 8, 2024 – Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced its preliminary, unaudited fourth quarter and full-year 2023 revenue results.

Highlights:

Preliminary revenue of $61.8 million to $62.2 million in the fourth quarter of 2023, an approximate 25% increase at the midpoint over the same period in 2022.

Preliminary revenue of $186.7 million to $187.1 million for the full-year 2023, an approximate increase of 32% at the midpoint compared to the prior year and above the high end of the previously provided revenue guidance range of $182 million to $186 million.

Preliminary blended average revenue per Lapiplasty® procedure kit sold in the fourth quarter of 2023 was approximately $6,437, a record high and 9% increase over the same period in 2022.

Substantial new active surgeon additions of approximately 164 in the fourth quarter of 2023 and approximately 468 for full-year 2023; Ended the year with approximately 2,855 active surgeons, a 20% increase compared to the prior year and approximately 29% of the estimated 10,000 U.S. surgeons performing bunion surgery.

Ended the fourth quarter of 2023 with 227 direct quota carrying sales representatives, a 35% increase over year-end 2022 and 82% revenue contribution in the fourth quarter of 2023.

“We delivered another year of significant progress in 2023 and expect to remain on track to drive strong growth and profitably scale our business in the years ahead,” said John T. Treace, CEO, Founder and Board Member of Treace. “We believe we are driving a market conversion in a large, underserved market as the fastest-growing, publicly-traded company in foot and ankle with differentiated bunion, midfoot, and related complementary technologies. We also believe we are in a great position strategically with an expanding addressable market opportunity with new technologies, such as our Adductoplasty®, Hammertoe and SpeedPlate™ products, and more innovations to come, supported by differentiating clinical studies, continued strong additions to our surgeon base and a powerful, focused commercial organization. We look forward to aggressively pursuing these significant opportunities to drive the performance of the business and believe we have all the elements in place to deliver strong growth and sustained market penetration in 2024 and beyond.”

2024 Outlook

Treace plans to provide 2024 financial guidance during its fourth quarter 2023 earnings conference call, which is currently scheduled for Tuesday, February 27, 2024 at 4:30 p.m. Eastern Time.

1


 

The preliminary unaudited financial information in this press release has not been subject to the more rigorous standards of review for Treace’s filed financial statements, may be adjusted, including as a result of its internal closing processes and the external auditing procedures of its independent registered public accounting firm, and remains subject to change until the Company files its full financial statements for 2023.

Treace to Present at J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024

John T. Treace, CEO, Founder and Board Member of Treace, will present at the J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 3:45 pm Pacific Time / 6:45 pm Eastern Time. Following this presentation, Mr. Treace will be joined by Mark Hair, CFO of Treace, for a question-and-answer session. A live webcast of this event, as well as an archived recording and presentation, will be available in the Investors section of Treace’s website at https://investors.treace.com/news-events/events-presentations.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements, including, but not limited to the Company’s anticipated fourth quarter and full-year 2023 revenue and fourth quarter 2023 blended average revenue per Lapiplasty® procedure kit sold, as well as its belief that the Company remains on track to drive strong growth and profitably scale its business in the years ahead, is driving a market conversion in a large, underserved market as the fastest-growing company in foot and ankle, is in a great position strategically with an expanding addressable market opportunity with new technologies and more innovations to come, and that it has all the elements in place to deliver strong growth and sustained market penetration in 2024 and beyond. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results or other events to differ materially from those contemplated in this press release can be found in the Risk Factors section of Treace’s public filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2022, and any subsequent Quarterly Report on Form 10-Q or Current Report on Form 8-K. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of their date and, except to the extent required by law, the Company undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise. The Company’s preliminary, unaudited results for the fourth quarter and full year ended December 31, 2023 reflect the Company’s current estimates based on information available as of the date of this press release and are subject to change, including as a result of the completion of the Company’s financial and operating closing procedures, customary audit procedures, and other developments that may occur before the completion of these procedures. Accordingly, you should not place undue reliance on these preliminary, unaudited results, which may differ materially from actual results and are not necessarily indicative of its operating results for any future periods.

Internet Posting of Information

Treace routinely posts information that may be important to investors in the “Investor” section of its website at www.treace.com. The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.

About Treace Medical Concepts

2


 

Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 65 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty®3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all 3 planes of the bunion deformity and address the root cause of the bunion, helping patients get back to their active lifestyles. Treace expanded its offering with the Adductoplasty® Midfoot Correction System, designed for reproducible correction of midfoot deformities, as well as its PEEK Hammertoe arthrodesis system, to further support the needs of bunion patients. The company continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlate™ Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty® and Adductoplasty® procedures, as well as other common bone fusion procedures of the foot. For more information, please visit www.treace.com.

To learn more about Treace, connect with us on LinkedIn, Twitter, Facebook, and Instagram.

Contacts:

Treace Medical Concepts, Inc.

Julie Dewey, IRC

Chief Communications & Investor Relations Officer

jddewey@treace.com | 209-613-6945






 



 



 


 


 


 

 

 

 

3


GRAPHIC 3 img32504678_0.jpg GRAPHIC begin 644 img32504678_0.jpg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end EX-101.SCH 4 tmci-20240108.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink Pre-commencement Issuer Tender Offer Entity Address, State or Province Trading Symbol Soliciting Material Entity Address, City or Town Written Communications CIK Entity Central Index Key Entity Tax Identification Number Registrant Name Entity Registrant Name Entity Ex Transition Period Period End Date Document Period End Date Entity Address, Postal Zip Code Entity Incorporation, State or Country Code Local Phone Number City Area Code Pre-commencement Tender Offer Cover Cover [Abstract] Security Exchange Name Entity Emerging Growth Company Amendment Amendment Flag Entity File Number Entity Address, Address Line Two Entity Address, Address Line One Title of 12(b) Security Security 12b Title Document Type Document Type XML 5 R1.htm IDEA: XBRL DOCUMENT v3.23.4
Document and Entity Information
Jan. 08, 2024
Cover [Abstract]  
Entity Tax Identification Number 47-1052611
Amendment Flag false
Entity Central Index Key 0001630627
Document Type 8-K
Document Period End Date Jan. 08, 2024
Entity Registrant Name TREACE MEDICAL CONCEPTS, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-40355
Entity Address, Address Line One 100 Palmetto Park Place
Entity Address, City or Town Ponte Vedra
Entity Address, State or Province FL
Entity Address, Postal Zip Code 32081
City Area Code 904
Local Phone Number 373-5940
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.001 par value per share
Trading Symbol TMCI
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 6 tmci-20240108_htm.xml IDEA: XBRL DOCUMENT 0001630627 2024-01-08 2024-01-08 false 0001630627 8-K 2024-01-08 TREACE MEDICAL CONCEPTS, Inc. DE 001-40355 47-1052611 100 Palmetto Park Place Ponte Vedra FL 32081 904 373-5940 false false false false Common Stock, $0.001 par value per share TMCI NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.treace.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports tmci-20240108.htm tmci-20240108.xsd http://xbrl.sec.gov/dei/2023 false false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tmci-20240108.htm": { "nsprefix": "tmci", "nsuri": "http://www.treace.com/20240108", "dts": { "inline": { "local": [ "tmci-20240108.htm" ] }, "schema": { "local": [ "tmci-20240108.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.treace.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_4e442569-f2e1-4ffe-b69c-887edfe91794", "name": "dei:EntityTaxIdentificationNumber", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "tmci-20240108.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_4e442569-f2e1-4ffe-b69c-887edfe91794", "name": "dei:EntityTaxIdentificationNumber", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "tmci-20240108.htm", "first": true, "unique": true } } }, "tag": { "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.treace.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.treace.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.treace.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.treace.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.treace.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.treace.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.treace.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.treace.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.treace.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.treace.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.treace.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.treace.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.treace.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.treace.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "CIK", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.treace.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.treace.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.treace.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.treace.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.treace.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.treace.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.treace.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.treace.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.treace.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.treace.com/20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 13 0000950170-24-002719-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-002719-xbrl.zip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end